Results 81 to 90 of about 125,964 (294)

Organizational structure and funding of health technology assessment agencies around the world

Фармакоэкономика, 2019
Aim: analyze the structure and funding of health technology assessment (HTA) agencies abroad.Materials and methods. Here, we review the organizational structure and funding of HTA agencies in Europe (Austria, Belgium, Germany, Ireland, the Netherlands ...
G. R. Khachatryan, V. V. Omelyanovskiy, L. S. Melnikova, S. S. Ratushnyak   +3 more
doaj   +1 more source

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies

ESC Heart Failure, 2021
Aims We applied the restricted mean survival time (RMST) to analyse the survival data reported in the PARADIGM‐HT trial in which sacubitril + valsartan was studied in comparison with enalapril in patients with heart failure.
Andrea Messori, Laura Bartoli, Sabrina Trippoli   +2 more
doaj   +1 more source

MAT: A Multimodal Attentive Translator for Image Captioning [PDF]

, 2017
In this work we formulate the problem of image captioning as a multimodal translation task. Analogous to machine translation, we present a sequence-to-sequence recurrent neural networks (RNN) model for image caption generation.
Liu, Chang, Sun, Fuchun, Wang, Changhu, Wang, Feng, Yuille, Alan   +4 more
core   +1 more source

Clinical effectiveness and safety of self-expandable implantable bulking agents for faecal incontinence: a systematic review

BMC Gastroenterology, 2022
Purpose The purpose of this systematic review is to evaluate whether self-expandable implantable vs non-self-expandable injectable bulking agents (second-line therapies) are equal/superior in terms of effectiveness (severity, quality of life [QoL]) and ...
Lucia Gassner, Claudia Wild, Melanie Walter   +2 more
doaj   +1 more source

Signals of threat do not capture, but prioritize, attention: a conditioning approach [PDF]

, 2011
Research suggests that threatening information captures attention more rapidly than neutral information. However, in most studies threat stimuli differ perceptually from neutral stimuli and are instrumental to perform the task, leaving the question ...
Crombez, Geert, De Houwer, Jan, Notebaert, Lies, Theeuwes, Jan, Van Damme, Stefaan   +4 more
core   +3 more sources

OP120 Developing A Call To Action For Patient Involvement In Health Technology Assessment (HTA) In Southern Africa [PDF]

, 2023
Lauren Pretorius, Debjani Mueller, Anke‐Peggy Holtorf   +2 more
openalex   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10

Journal of Comparative Effectiveness Research, 2022
In this latest update we discuss the transportability of comparative effectiveness evidence across countries. We highlight results of a survey indicating that European HTA agencies are reluctant to accept real-world data from other countries, review ...
Alex Simpson, Sreeram V Ramagopalan
doaj   +1 more source

Mechanism Design with Limited Commitment [PDF]

, 2020
We develop a tool akin to the revelation principle for mechanism design with limited commitment. We identify a canonical class of mechanisms rich enough to replicate the payoffs of any equilibrium in a mechanism-selection game between an uninformed ...
Doval, Laura, Skreta, Vasiliki
core   +1 more source

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment : A Systematic Review of the Literature. [PDF]

, 2017
Introduction: Although pharmaceutical companies, regulatory authorities, and health technology assessment (HTA) agencies have been increasingly using decision-making frameworks, it is not certain whether these enable better quality decision making.
*, *, Beyer, Blenko, Buchanan, Bujar, Bujar, Calnan, Canadian Agency for Drugs and Technologies in Health (CADTH), Cherny, Cole, Cook, Cowlrick, Dean, Donelan, Donelan, Dowding, EUnetHTA, European Medicines Agency (EMA), European Medicines Agency (EMA), European Medicines Agency (EMA), Fischer, Food and Drug Administration (FDA), Food and Drug Administration (FDA), Garbuio, Goldberg, Guo, Hammond, Hassanzadeh, Jekunen, Kahneman, Leong, Liberti, Lovallo, Marangi, Matheson, Matheson, McAuslane, McAuslane, McDowell, McIntyre, Morton, Pignatti, Ratliff, Rogowski, Salek, Schnipper, Scott, Sharpe, Strategic Decision Group (SDG), Streiner, Thaler, Wagner, Westley, World Health Organization (WHO)   +54 more
core   +2 more sources